Compare Kaltura Inc (KLTR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs TG Therapeutics Inc — how do they compare? Kaltura Inc trades at $1.35 (market cap $208.27M), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is far larger — about 39.7× Kaltura Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals.
| KLTR | TGTX | |
|---|---|---|
Market Cap | $208.27M | $8.26B |
Sector | Technology | Health |
52-Week High | $1.97 | $59.06 |
52-Week Low | $1.08 | $26.39 |
Enterprise Value | $190.99M | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kaltura (KLTR) trades at $1.43, up 2.88% on the day, with a bullish technical signal. The company shows improving fundamentals, with revenue stabilizing around $180M and net losses narrowing significantly from -$68M in 2022 to -$12M in 2025. Recent quarters have consistently beaten EPS expectations, and the company has garnered multiple industry awards, highlighting its leadership in agentic digital experience platforms.
The outlook is cautiously optimistic, with a path to profitability emerging, but risks remain from high debt levels and negative ROE. Analyst sentiment is mixed but leans positive, with 44% recommending Buy. The stock's valuation appears stretched on a P/B basis, requiring sustained execution for further upside.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
